- 563studies in the library match, of 29,780
- 209name it in the title
- 1983–2026years published
- 546peer-reviewed articles
The query: title or abstract mentions "early-onset", "young-onset" or "younger-onset" Alzheimer's/dementia, "EOAD", "YOAD", "autosomal dominant Alzheimer", "before/under the age of 65" or "under 65", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 29,780 study records, as of 2026-11-09. Every count on this page comes from that match. The matched list as JSON.
Early-onset Alzheimer's is the same disease process as the common late-onset form, but it begins while people are still working, raising children or caring for parents, which changes everything about diagnosis and support. A minority of early-onset cases are caused by a single inherited mutation in the APP, PSEN1 or PSEN2 gene, passed down in a dominant pattern; most are not, and have the same mix of genetic and lifestyle risk as later-onset disease.
Younger patients more often present with problems other than memory, such as language, vision or planning difficulties, so diagnosis is often delayed. Research cohorts set up specifically for early-onset disease study its biology, imaging and course, and the inherited form has been central to prevention trials because the age of onset can be predicted.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person: a doctor who knows the person's history is the only one who can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 563 matched records are quoted; each links to its study page and from there to the paper.
“These findings indicate the potential clinical utility of amyloid imaging for differential diagnosis in early-onset dementia and to support the clinical diagnosis of participants with AD dementia and noncarrier APOE ε4 status who are older than 70 years.”
“These effects were sustained in individuals over the age of 65 but not in those under 65.”
“Global age-standardized prevalence of young-onset dementia (ages 30-64) was 119.0 per 100,000 population”
“Previously reported pathogenic variants in the six genes were identified in 1.35% of EOAD (3/223) and 6.58% of EOnonAD (5/76).”
“Interpretation Our findings in autosomal dominant Alzheimer's disease position the TREM2 response within the amyloid cascade immediately after the first pathological changes in Aβ aggregation and further support the role of TREM2 on Aβ plaque deposition and compaction.”
“Low frequency coding variants in TREM2 are associated with increased Alzheimer disease (AD) risk, while loss of functions mutations in the gene lead to an autosomal recessive early-onset dementia, named Nasu-Hakola disease (NHD).”
“In conclusion, adults with ASD under the age of 65 were approximately 2.6 times more likely to be diagnosed with dementia compared to the general population in our study.”
“Of the 57 353 (5·2%) cases of early-onset dementia, most were either alcohol-related by definition (22 338 [38·9%]) or had an additional diagnosis of alcohol use disorders (10 115 [17·6%]).”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 13 |
| Randomised controlled trial | 1 |
| Other clinical trial | 3 |
| Cohort or longitudinal study | 58 |
| Case-control study | 6 |
| Cross-sectional study | 32 |
| Other recorded design | 3 |
| No design recorded | 447 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 33 | |
| 2025 | 65 | |
| 2024 | 28 | |
| 2023 | 31 | |
| 2022 | 27 | |
| 2021 | 27 | |
| 2020 | 29 | |
| 2019 | 23 | |
| 2018 | 27 | |
| 2017 | 23 | |
| 2016 and earlier | 250 |
Other counts within the matched set
| Peer-reviewed articles | 546 |
| Marked open access in the record | 161 |
| Rated "high" evidence strength in alzhub's summary | 18 |
| Rated "moderate" evidence strength in alzhub's summary | 115 |
| Rated "low" evidence strength in alzhub's summary | 424 |
| No evidence-strength rating | 6 |
| Records stating a participant count | 181 |
| Median participants (those records) | 156 |
| Largest participant count | 2,760,379 |
Within the 563 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that mention APP, PSEN1 or PSEN2 | 232 | the abstract also contains "PSEN1", "PSEN2", "presenilin", "APP mutation/duplication/gene" or "amyloid precursor protein" |
| …that also mention APOE | 66 | the abstract also contains "APOE" or "apolipoprotein E" |
| …that compare with late-onset disease | 114 | the abstract also contains "late-onset" or "LOAD" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
- Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study
- Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis
- Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis
- Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis
- Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort
- Risk Factors for Young-Onset Dementia in the UK Biobank
- APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease
- Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study
- Plasma biomarker profiles in autosomal dominant Alzheimer's disease
Systematic reviews and meta-analyses in the set
13 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration
- Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing
- TREM2 variants in Alzheimer's disease
- Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis
- Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis
Newest matched studies
- Too early for LATE? Age at onset is associated with the clinical and neuroimaging expression of limbic-predominant age- related TDP-43 pathology in Alzheimer’s disease
- Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing
- Person-centred care in the early post-diagnostic phase of young-onset dementia: co-created insights from service users and professionals through participatory action research
- Cannabidiol for chronic neuroinflammation: clinical pharmacology and what an interpretable trial will require
- Large-scale cerebrospinal fluid proteomics identifies diagnostic biomarker candidates across the clinico-pathological continuum of frontotemporal lobar degeneration
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 27 |
| Neurology | 26 |
| Brain : a journal of neurology | 20 |
| The Lancet. Neurology | 19 |
| Neurobiology of aging | 17 |
Questions
- Is early-onset Alzheimer's always inherited?
- No. A small share is caused by a single dominant mutation in APP, PSEN1 or PSEN2, and in those families roughly half of each generation inherits it. Most early-onset cases have no such mutation and arise from the same mix of risks as late-onset disease.
- How many studies on early-onset alzheimer's does alzhub hold?
- 563 of the 29,780 study records in alzhub's library match the query "title or abstract mentions "early-onset", "young-onset" or "younger-onset" Alzheimer's/dementia, "EOAD", "YOAD", "autosomal dominant Alzheimer", "before/under the age of 65" or "under 65""; 209 of them name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 13 systematic review or meta-analysis, 1 randomised controlled trial, 3 other clinical trials, 58 cohort or longitudinal studys, 6 case-control studys, 32 cross-sectional studys; 447 record no design.
- What is the most recent study in the set?
- "Too early for LATE? Age at onset is associated with the clinical and neuroimaging expression of limbic-predominant age- related TDP-43 pathology in Alzheimer’s disease" (medRxiv, 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Alzheimer's & dementia : the journal of the Alzheimer's Association (27); Neurology (26); Brain : a journal of neurology (20), counted across the matched records.
Read on
- Is Alzheimer's hereditary?The inherited forms and APOE.
- Frontotemporal dementiaThe most common dementia in people under 60.
- GeneticsAPOE and the other risk genes, in plain language.